Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global’s SEC disclosures dive deep into calcification studies, trial endpoints, and FDA milestones for its DurAVR THV system—details that can overwhelm even seasoned med-tech analysts. Finding when executives buy shares or how R&D spending shifts between valve iterations inside a 300-page filing is an added challenge.
Stock Titan solves that by pairing every submission with AI-powered summaries and plain-English tags. Whether you need the "Anteris Technologies insider trading Form 4 transactions" or the most recent "Anteris Technologies quarterly earnings report 10-Q filing", the platform pulls them the moment they hit EDGAR and explains what each metric means for market size, reimbursement pathways, and capital needs. You’ll see "Anteris Technologies Form 4 insider transactions real-time", "Anteris Technologies SEC filings explained simply", and "Anteris Technologies earnings report filing analysis" side-by-side with source PDFs, saving hours of manual scrolling.
Looking for deeper context? Our tools highlight how trial data in an 8-K could influence future approvals, compare pipeline costs across periods, and flag changes in covenant language that impact liquidity. It’s "understanding Anteris Technologies SEC documents with AI"—from the "Anteris Technologies executive stock transactions Form 4" to the "Anteris Technologies annual report 10-K simplified", the "Anteris Technologies proxy statement executive compensation" and even "Anteris Technologies 8-K material events explained". Track insider sentiment before a pivotal catalyst, gauge quarterly burn rate, or review governance terms in seconds. All filings, all in one place, translated into actionable insights so you can focus on investment decisions, not document hunting.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
The current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR) is $3.07 as of August 1, 2025.
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
The market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR) is approximately 124.2M.
What is the primary focus of ANTERIS TECHNOLOGIES GLOBAL?
ANTERIS TECHNOLOGIES GLOBAL focuses on the development and commercialization of structural heart devices, specifically targeting the treatment of aortic stenosis through advanced biomimetic valve technology.
What is the DurAVR THV system?
The DurAVR THV system is a novel heart valve replacement product that uses proprietary ADAPT tissue-enhancing technology to create a single-piece, biomimetic valve deployed via a balloon-expandable delivery system.
How does the ADAPT technology enhance the valve design?
ADAPT technology reengineers xenograft tissue into a pure collagen bioscaffold, reducing calcification risks and improving the durability and performance of the biomimetic valve deployed for aortic stenosis.
What differentiates ANTERIS TECHNOLOGIES GLOBAL from other structural heart device companies?
Its unique integration of ADAPT tissue-enhancing technology and the ComASUR delivery system sets it apart, providing a differentiated approach to address the anatomical and functional challenges associated with aortic stenosis.
How does the company generate revenue?
Revenue is primarily generated through the direct sale of its medical devices after thorough clinical validations and adherence to regulatory standards, ensuring that the products meet the required medical efficacy and safety benchmarks.
In which market segment does the company operate?
The company operates in the specialized structural heart and cardiac device segment, addressing critical needs in the treatment of valvular heart diseases, particularly aortic stenosis.
What are the clinical applications of the DurAVR THV system?
The DurAVR THV system is designed for patients with aortic stenosis, offering an alternative to traditional heart valve replacement therapies by providing a biomimetic valve that mimics natural heart function and may improve patient outcomes.
How does ANTERIS TECHNOLOGIES GLOBAL ensure regulatory compliance?
The company implements robust clinical validations and adheres to stringent regulatory standards to ensure that its innovative medical devices meet all quality, safety, and efficacy requirements expected in the highly regulated healthcare industry.